NovoCure Ltd. (NVCR) PT Raised to $48 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
NovoCure Ltd. (NVCR) PT Raised to $58 at Mizuho Securities
September 6, 2018 8:48 AM EDTMizuho Securities analyst Difei Yang raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $58.00 (from $44.00) while maintaining a Buy rating following the company's final results from the STELLAR phase 2 trial of Optune plus.
Data was impressive, with an overall survival benefit of 6.1 months... More
